The ANXA7 Knockout A-549 Polyclonal Cells product is a heterogeneous population of CRISPR/Cas9-edited A-549 lung adenocarcinoma cells with targeted disruption of the ANXA7 gene. This polyclonal knockout pool, generated without clonal isolation, provides a loss-of-function model that retains genetic diversity, reflecting the complexity of tumor cell populations. It is designed for studying the role of ANXA7 in membrane dynamics and signal transduction in lung cancer.
The parental A-549 cell line, derived from a 58-year-old male with lung carcinoma, is a widely used adherent epithelial model for non-small cell lung cancer (NSCLC). These cells display alveolar basal epithelial features and are routinely employed in oncology for drug sensitivity screening, migration/invasion assays, and signaling studies. Engineering ANXA7 knockout in this background enables direct interrogation of its functions in lung adenocarcinoma.
ANXA7 encodes a calcium-dependent phospholipid-binding protein involved in membrane fusion, exocytosis, and apoptosis. It is activated by EGF and calcium influx and is regulated by p53. ANXA7 interacts with F-actin, ALG-2, and S100 proteins, modulating membrane organization and EGFR recycling. In EGFR signaling, ANXA7 influences downstream MAPK/ERK cascade components including GRB2, SOS, RAS, RAF, MEK, and ERK. It also affects apoptosis through BCL2 and BAX, and impacts MMP secretion. Disruption of ANXA7 perturbs calcium-sensitive membrane dynamics, altering mitogenic and anti-apoptotic signaling strength.
In A-549 NSCLC cells, ANXA7 knockout disrupts EGFR trafficking and MAPK/ERK signaling, impairing cell migration, invasion, and apoptotic regulation??consistent with a tumor-suppressive role. The polyclonal nature allows assessment of heterogeneous responses, providing a physiologically relevant model. This loss-of-function system in a well-characterized lung adenocarcinoma background facilitates dissection of ANXA7-dependent tumor progression mechanisms.
These polyclonal knockout cells are suitable for EGFR-targeted drug screening, transwell migration, Matrigel invasion, and Annexin V apoptosis assays. Signaling outputs can be measured via phospho-ERK ELISA, RT-qPCR, and co-immunoprecipitation of interactors like ALG-2. Additional applications include calcium imaging and MTT proliferation assays, supporting lung cancer functional genomics and drug resistance research. For more information, please contact Ascent Research.
